Sanofi SA vs Twilio Inc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Twilio Inc trades at $195.99 (market cap $31.15B). The key difference: Sanofi SA is far larger — about 3.4× Twilio Inc's market cap, and Sanofi SA pays a 5.5% dividend while Twilio Inc pays none. Which is the better fit depends on your goals.
| SNY | TWLO | |
|---|---|---|
Market Cap | $104.83B | $31.15B |
Sector | Health | Technology |
52-Week High | $52.34 | $236.64 |
52-Week Low | $41.33 | $92.44 |
Enterprise Value | $121.32B | $29.87B |
Dividend Yield | 5.5% | — |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →